|
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects |
|
|
|
Titel: |
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects |
Auteur: |
Xu, Zhongnan Wang, Yanli Liu, Zhengzhi Zhang, Renjie Zhou, Yannan Yu, Jing Lan, Jing Liang, Wenzhong Liu, Guangwen Qu, Xinyao Chen, Jiahui Su, Zhengjie Yu, Shuang Cheng, Yang Wang, Wanhua Ren, Qing Deng, Qiaohuan Zhao, Yicheng Yang, Haimiao |
Verschenen in: |
International immunopharmacology |
Paginering: |
Jaargang 109 () nr. C pagina's p. |
Jaar: |
2022 |
Inhoud: |
|
Uitgever: |
Elsevier B.V. |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|